|Bid||44.50 x 1100|
|Ask||45.00 x 4000|
|Day's Range||44.40 - 44.90|
|52 Week Range||37.80 - 46.97|
|Beta (5Y Monthly)||0.37|
|PE Ratio (TTM)||18.07|
|Earnings Date||Feb 01, 2017 - Feb 06, 2017|
|Forward Dividend & Yield||1.99 (4.48%)|
|Ex-Dividend Date||May 19, 2022|
|1y Target Est||49.81|
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
The British drugmaker recently announced that it agreed to acquire a late-stage biopharmaceutical company.
Pharmaceutical giant GlaxoSmithKline (NYSE: GSK) missed out on this early action and now looks to launch several pandemic products this year. GSK has three separate COVID vaccines in late-stage development, in various partnerships with Sanofi (NASDAQ: SNY), South Korean pharmaceutical SK bioscience, and Canadian biopharmaceutical Medicago. GSK's Phase 3 clinical trials are wrapping up, and GSK expects regulatory decisions in the US and EU starting later this year.